NANO-X IMAGING Reports Fourth Quarter Earnings Results for FY2022 on March 9, 2023.

Earnings Overview

On March 9, 2023, NANO-X IMAGING ($NASDAQ:NNOX) reported its earnings results for the fourth quarter of FY2022 (ending December 31, 2022), revealing total revenue of USD -44.8 million, a decrease of 103.4% year-over-year. Net income was USD 2.1 million, a 63.8% increase compared to the same quarter in the previous year.

Transcripts Simplified

My name is Name, and I’ll be your host for today’s conference. At this time, all participants are in a listen-only mode. Later, we will have a question-and-answer session.

Net income for the quarter was approximately $2 million, compared to a net loss of $1 million in the prior year period. Thank you for joining us today.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Nano-x Imaging. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Nano-x Imaging. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Nano-x Imaging. More…

Key Ratios Snapshot

Some of the financial key ratios for Nano-x Imaging are shown below. More…

Share Price

Stock prices opened at $6.5 and closed at $6.5, representing a drop of 6.2% from the previous closing price of 7.0. Overall, NANO-X IMAGING reported a strong quarter, showing a significant improvement in both growth and profitability. The company’s stock price dropped on Thursday, but with its strong financial results, investors remain optimistic about the future of the company and its prospects for further growth. Live Quote…

Analysis

At GoodWhale, we have conducted an analysis of NANO-X IMAGING‘s wellbeing. After our review, we have given them a Risk Rating of high. This means that this investment is risky in terms of its financial and business aspects. We have detected 2 risk warnings in their cashflow statement and financial journal. If you are a registered user of GoodWhale, you can access our full report on the company, including these risk warnings. We recommend that investors proceed with caution when considering this investment. More…

Peers

The company’s products include the Nano X Ray System, a portable x-ray system that uses nanotechnology to generate high-resolution images; and the Nano X CT System, a nanotechnology-based computed tomography system that produces 3D images of the human body. Nano X Imaging’s competitors include Japan Vietnam Medical Instrument JSC, Medicalgorithmics SA, and EMvision Medical Devices Ltd.

– Japan Vietnam Medical Instrument JSC ($HOSE:JVC)

Vietnam Medical Instrument JSC is a medical equipment company located in Vietnam. As of 2022, the company has a market capitalization of 320.63 billion VND. The company’s Return on Equity (ROE) for the same year is -2.94%.

Vietnam Medical Instrument JSC is engaged in the manufacture and sale of medical equipment and supplies. The company offers a wide range of products, including X-ray machines, ultrasound machines, medical beds, and surgical instruments. It also provides services, such as repairs and maintenance of medical equipment.

– Medicalgorithmics SA ($LTS:0QR8)

Algorithmics SA is a publicly traded company with a market capitalization of 61.71M as of 2022. The company’s return on equity is 1662.69%, meaning that it has generated a significant amount of shareholder value. Algorithmics SA is a provider of software and services for the financial services industry. The company’s products and services are used by banks, insurance companies, and other financial institutions to manage risk and compliance.

– EMvision Medical Devices Ltd ($ASX:EMV)

EMvision Medical Devices Ltd is a medical device company that develops and commercializes 3D and 4D medical imaging products. The company has a market cap of 131.68M as of 2022 and a Return on Equity of -43.39%. EMvision’s products are used for the diagnosis and treatment of various conditions, including cancer, cardiovascular disease, and neurological disorders. The company’s products are sold worldwide.

Summary

NANO-X IMAGING reported a Q4 FY2022 revenue of -44.8 million, a 103.4% decrease from the previous year’s quarter. Despite this, the company managed to achieve a net income of 2.1 million, a 63.8% increase from the corresponding quarter from the previous year. This resulted in a stock price decline on the same day.

For investors considering NANO-X IMAGING, they should note that while the company has managed to reduce losses, the decrease in revenue could be a sign of major challenges ahead. They should also consider analyzing the company’s financials and industry trends in order to make a more informed investment decision.